IMVIF.US IMV Inc.
- Market cap
- USD 23.4K
- P/E
- -
- P/B
- 8.87x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is IMVIF.US undervalued?
Graham numberThe Graham number of IMV Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMV Inc. fundamental analysis
No fundamental analysis for IMV Inc. yet.
IMV Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in…
Full company profileIMV Inc. financial statements
IMV Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 93.5K | 131K | 33.5K | 81.7K | 45.5K | 3.16K | 0.00 | 0.00 |
| Gross Profit | -109K | -98.4K | - | 131K | -108K | 81.7K | 45.5K | 3.16K | -536K | -962K |
| Operating Income | -6.05M | -7.31M | -8.79M | -8.27M | -12.5M | -15.4M | -22.4M | -35.3M | -40.2M | -38.7M |
| EBITDA | -5.94M | -7.22M | -5.96M | -8.19M | -12.4M | -21.5M | -19.6M | -28.4M | -36.4M | -35.5M |
| Net Income | -4.44M | -6.28M | -6.32M | -8.96M | -12.2M | -21.9M | -20.9M | -27.4M | -36.3M | -36.5M |
| EPS | -2.07 | -2.41 | -2.20 | -2.84 | -3.16 | -5.00 | -4.22 | -4.55 | -4.89 | -4.37 |
| Balance Sheet | ||||||||||
| Total Assets | 4.79M | 10.7M | 4.29M | 15.2M | 17.3M | 22.9M | 17.3M | 46.0M | 50.1M | 31.3M |
| Total Liabilities | 2.35M | 3.99M | 4.24M | 8.18M | 10.8M | 18.5M | 12.3M | 15.2M | 28.5M | 38.0M |
| Shareholders' Equity | 2.43M | 6.73M | 50.0K | 7.03M | 6.44M | 4.30M | 4.95M | 30.8M | 21.5M | -6.60M |
| Cash & Short-term Investments | 3.32M | 9.18M | 2.77M | 13.6M | 15.1M | 14.8M | 10.8M | 36.3M | 38.6M | 21.2M |
| Total Debt | 1.25M | 2.75M | 2.72M | 6.19M | 6.63M | 9.52M | 7.53M | 7.97M | 19.6M | 28.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.49M | -4.22M | -5.09M | -6.09M | -9.13M | -17.1M | -28.0M | -24.8M | -31.8M | -32.1M |
| Capital Expenditure | 6.25K | 33.5K | 87.2K | 112K | 393K | 2.18M | 367K | 348K | 1.39M | 1.07M |
| Free Cash Flow | -4.50M | -4.25M | -5.18M | -6.20M | -9.52M | -19.3M | -21.4M | -25.1M | -33.2M | -33.1M |
| Ratios | ||||||||||
| ROE | -182.7% | -93.3% | -12,651.8% | -127.4% | -189.6% | -508.1% | -423.0% | -89.1% | -168.6% | - |
| ROA | -92.9% | -58.5% | -147.4% | -58.9% | -70.6% | -95.7% | -121.1% | -59.6% | -72.5% | -116.4% |
| Net Profit Margin | - | - | -6,765.4% | -6,858.7% | -36,447.1% | -26,750.0% | -46,043.7% | -868,765.3% | - | - |
| Debt to Equity | 0.51x | 0.41x | 54.46x | 0.88x | 1.03x | 2.21x | 1.52x | 0.26x | 0.91x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IMV Inc. dividends
IMV Inc. has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Dec 13, 2022.
Who owns IMV Inc.
Ownership data of IMV Inc. is not available yet.
IMV Inc. company profile
- Company name
- IMV Inc.
- Ticker
- IMVIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- December
- Address
- 130 Eileen Stubbs Avenue, Dartmouth, NS, Canada, B3B 2C4
- Phone
- 902 492 1819
- Website
- -
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IMV Inc. management
3- Mr. Andrew Hall M.Sc.CEO & Director
- Ms. Brittany Davison C.A., CPACorporate Secretary & Director · born 1990
- Mr. Stephan Fiset M.B.A., M.Sc.Vice President of Clinical Research